↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Tyck till om SwePub Sök här!

Träfflista för sökning "WFRF:(Ullén A.) "

Sökning: WFRF:(Ullén A.)

Resultat 21-30 av 141

Sortera/gruppera träfflistan

Sortering: Träffar per sida:

Numrering	Referens	Omslagsbild	Hitta
21.	Sridhar, SS, et al. (författare) Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance 2024 Ingår i: European urology. - 1873-7560. ; 85:2, s. 154-163 Tidskriftsartikel (refereegranskat)
22.	ULLEN, A, et al. (författare) Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization 1995 Ingår i: Cell biophysics. - 0163-4992. ; 27:1, s. 31-45 Tidskriftsartikel (refereegranskat)
23.	Benedict, A, et al. (författare) Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma 2011 Ingår i: BJU international. - 1464-410X. ; 108:5, s. 665-672 Tidskriftsartikel (refereegranskat)
24.	Bergengren, Oskar, et al. (författare) Short term outcomes after robot assisted and open cystectomy- A nation-wide population-based study 2023 Ingår i: Ejso. - : Elsevier BV. - 0748-7983 .- 1532-2157. ; 49:4, s. 868-874 Tidskriftsartikel (refereegranskat)abstract Introduction: We aimed to compare short term outcomes after robot assisted radical cystectomy (RARC) and open radical cystectomy (ORC) for urinary bladder cancer in a large population.Materials and methods: We included all patients without distant metastases who underwent either RARC or ORC with ileal conduit between 2011 and 2019 registered in the Bladder cancer data Base Sweden (BladderBaSe) 2.0. Primary outcome was unplanned readmissions within 90 days, and secondary out-comes within 90 days of surgery were reoperations, Clavien 3-5 complications, total days alive and out of hospital, and mortality. The analysis was carried out using multivariate regression models.Results: Out of 2905 patients, 832 were operated with RARC and 2073 with ORC. Robotic procedures were to a larger extent performed during later years, at high volume centers (47% vs 17%), more often for organ-confined disease (82% vs. 72%) and more frequently in patients with high socioeconomic status (26% vs. 21%). Patients operated with RARC were more commonly readmitted (29% vs. 25%). In multi -variable analysis RARC was associated with decreased risk of Clavien 3-5 complications (OR 0.58, 95% CI 0.47-0.72), reoperations (OR 0.53, 95% CI 0.39-0.71) and had more days alive and out of hospital (mean difference 3.7 days, 95% CI 2.4-5.0).Conclusion: This study illustrates the "real-world" effects of a gradual and nation-wide introduction of RARC. Patients operated with RARC had fewer major complications and reoperations but were more frequently readmitted compared to ORC. The observed differences were largely due to more wound related complications among patients treated with ORC.(c) 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
25.	Bjaras, G, et al. (författare) Strategies and methods for implementing a community-based diabetes primary prevention program in Sweden 1997 Ingår i: HEALTH PROMOTION INTERNATIONAL. - : Oxford University Press (OUP). - 0957-4824 .- 1460-2245. ; 12:2, s. 151-160 Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
26.	Dankiewicz, Josef, et al. (författare) Targeted hypothermia versus targeted Normothermia after out-of-hospital cardiac arrest (TTM2): A randomized clinical trial - Rationale and design 2019 Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 217, s. 23-31 Tidskriftsartikel (refereegranskat)abstract Background: Less than 500 participants have been included in randomized trials comparing hypothermia with regular care for out-of-hospital cardiac arrest patients, and many of these trials were small and at a high risk of bias. Consequently, the accrued data on this potentially beneficial intervention resembles that of a drug following small phase II trials. A large confirmatory trial is therefore warranted. Methods: The TTM2-trial is an international, multicenter, parallel group, investigator-initiated, randomized, superiority trial in which a target temperature of 33°C after cardiac arrest will be compared with a strategy to maintain normothermia and early treatment of fever (≥37.8°C). Participants will be randomized within 3 hours of return of spontaneous circulation with the intervention period lasting 40 hours in both groups. Sedation will be mandatory for all patients throughout the intervention period. The clinical team involved with direct patient care will not be blinded to allocation group due to the inherent difficulty in blinding the intervention. Prognosticators, outcome-assessors, the steering group, the trial coordinating team, and trial statistician will be blinded. The primary outcome will be all-cause mortality at 180 days after randomization. We estimate a 55% mortality in the control group. To detect an absolute risk reduction of 7.5% with an alpha of 0.05 and 90% power, 1900 participants will be enrolled. The main secondary neurological outcome will be poor functional outcome (modified Rankin Scale 4–6) at 180 days after arrest. Discussion: The TTM2-trial will compare hypothermia to 33°C with normothermia and early treatment of fever (≥37.8°C) after out-of-hospital cardiac arrest. © 2019
27.	Erlandsson, Ann, et al. (författare) Interaction studies between the antigen cytokeratin 8 and idiotypic-antiidiotypic monoclonal antibodies 1998 Konferensbidrag (populärvet., debatt m.m.)
28.	Farnebo, J, et al. (författare) Progression-free and overall survival in metastatic castration-resistant prostate cancer treated with abiraterone acetate can be predicted with serial C11-acetate PET/CT 2016 Ingår i: Medicine. - 1536-5964. ; 95:31, s. e4308- Tidskriftsartikel (refereegranskat)
29.	Grivas, P, et al. (författare) Avelumab first-line (1L) maintenance plus best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100 2020 Ingår i: ANNALS OF ONCOLOGY. - : Elsevier BV. - 0923-7534. ; 31, s. S555-S556 Konferensbidrag (övrigt vetenskapligt/konstnärligt)
30.	Grivas, P, et al. (författare) Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial 2023 Ingår i: European urology. - 1873-7560. ; 84:1, s. 95-108 Tidskriftsartikel (refereegranskat)

Skapa referenser, mejla, bekava och länka

Länka till träfflistan

Resultat 21-30 av 141

Avgränsa träffmängd

Typ av publikation: tidskriftsartikel (118); konferensbidrag (19); doktorsavhandling (2); annan publikation (1); bokkapitel (1)

Typ av innehåll: refereegranskat (105); övrigt vetenskapligt/konstnärligt (34); populärvet., debatt m.m. (2)

Författare/redaktör: Ullen, A (104); Stigbrand, T. (28); Nilsson, S. (18); Sandstrom, P. (16); Ullén, Fredrik (15); Stigbrand, Torgny (14); visa fler...; Mosing, Miriam A. (13); Riklund, Katrine (12); Johansson, A (12); Madison, Guy (11); Ströck, Viveka (11); Ullén, Anders (11); Ullen, F (11); Jerlström, Tomas, 19 ... (10); Sundström, Birgitta (10); Sandström, P. (10); Sherif, Amir (9); Liedberg, Fredrik (9); Hosseini, A. (9); Park, SH (9); Loriot, Y (9); Holmsten, K (9); Grivas, P (9); Di Pietro, A (8); Erlandsson, A (8); Powles, T. (8); Pappot, H (8); Gurney, H (8); Sternberg, CN (8); Johansson, H (7); Jahnson, Staffan (7); Gardmark, T. (7); Hietala, Sven-Ola (7); Pedersen, Nancy L (7); Nilsson, B (7); Yachnin, J (7); Huang, B. (7); Söderkvist, Karin (7); Hietala, SO (7); Demey, W (7); Häggström, Christel (6); Malmström, Per-Uno (6); Holmberg, Lars (6); Hagberg, Oskar (6); Harmenberg, U. (6); PanaretakiS, T (6); Brandberg, Y (6); Costa, N (6); Erlandsson, Ann (6); Voog, E (6); visa färre...

Lärosäte: Karolinska Institutet (118); Umeå universitet (39); Göteborgs universitet (16); Uppsala universitet (13); Lunds universitet (13); Örebro universitet (12); visa fler...; Linköpings universitet (9); Karlstads universitet (9); Stockholms universitet (3); Kungliga Tekniska Högskolan (2); Handelshögskolan i Stockholm (2); Linnéuniversitetet (1); RISE (1); Naturhistoriska riksmuseet (1); visa färre...

Språk: Engelska (139); Latin (2)

Forskningsämne (UKÄ/SCB): Medicin och hälsovetenskap (40); Samhällsvetenskap (15); Naturvetenskap (3); Humaniora (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - Nationella bibliotekssystem
LIBRIS.kb.se

pil uppåt

Stäng

Kopiera och spara länken för att återkomma till aktuell vy